Moderna’s stock more than doubled on Wednesday after the vaccine maker and partner Merck reported that their personalized mRNA cancer vaccine, code-named mRNA-4157 (V940), hit its goal in a late-stage trial for patients with melanoma. Shares climbed roughly 90 percent in premarket trading, briefly touching about $120, up from around $63 in the prior session, according to MarketWatch and BioSpace.
What the trial shows
The Phase 3 result combines Moderna’s personalized cancer vaccine, built around each patient’s tumor mutations, with Merck’s immunotherapy Keytruda. For people with resected high risk melanoma, the combination proved effective enough to clear the trial’s primary goal, backing up the smaller Phase 2 data that had already signaled a meaningful drop in recurrence.
Why the market reacted so hard
Investors have been waiting years for Moderna to prove its mRNA platform works beyond COVID. A win here is a signal that the technology can be tuned to attack cancer, opening up a potential treatment market far larger than a single jab. That is why a late stage success translates into a double on the stock rather than a modest bump.
What it means in context
The move is a contrast to the broader bloodletting in once-hot momentum stocks and a reminder that genuine scientific milestones still move markets. It also fits the growing pile of artificial intelligence and biotech stories reshaping how investors pick bets. Moderna still faces years of regulatory review before mRNA-4157 could reach patients, but Wednesday was the kind of day its long-term thesis has been waiting for.
